Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 451Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Triple Negative Breast Neoplasms 162Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 141Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 74Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Small Cell Lung Carcinoma 39Glioblastoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Lymphoma 34

Interventions

Cyclophosphamide 2toripalimab 1pembrolizumab 1fludarabine 1apatinib 1TP protocol 1Surgical Procedures, Operative 1Radiation 1Heavy Ion Radiotherapy 1Drug Therapy 1Doxorubicin 1Cisplatin 1Carboplatin 1AP 1903 reagent 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thymic epithelial tumor × pembrolizumab × Clear all
NCT03858582 2021-03-22

neoadjuvant_thymic Epithelial Tumor

Samsung Medical Center

Phase 2 Unknown
40 enrolled

Thymic epithelial tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡